The Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity Medicine
Published Date: 03.25.2026
GLP-1 receptor agonists built a $71 billion market by making patients eat less. But the body has more than one appetite switch. Amylin, a hormone co-secreted with insulin that the pharmaceutical industry abandoned after a string of clinical failures in the 2000s, is now the hottest target in obesity drug development. In the last eighteen months, Novo Nordisk filed for FDA approval of CagriSema, the first GLP-1/amylin combination. Eli Lilly advanced eloralintide to Phase 3 on 20.1% weight loss data. Roche paid $5.3 billion for petrelintide. Pfizer paid $10 billion for Metsera’s amylin pipeline. AbbVie committed $2.2 billion for a Phase 1 amylin analog. Thirty-nine programs are in development. The deals are public. The clinical data is converging. The question that will determine which become twenty-year franchises is the same one most investors can’t answer: what separates the programs that are building defensible positions from the ones renting their market share? We reviewed the landscape to find out.
MDB Capital is a wholly-owned subsidiary of MDB Capital Holdings (Nasdaq: MDBH) and a broker-dealer registered with the U.S. Securities and Exchange Commission, a member of FINRA and a member of SIPC. Securities trading, account management, and investment banking services are offered by MDB Capital.
PatentVest, Inc. is a wholly owned subsidiary of MDB Capital Holdings and an affiliated company of MDB Capital.
